Retrieve available abstracts of 51 articles: HTML format
Single Articles
May 2025
GILBERT FJ, Payne NR, Allajbeu I, Yit L, et al Comparison of supplemental breast cancer imaging techniques-interim results from
the BRAID randomised controlled trial.
Lancet. 2025 May 21:S0140-6736(25)00582-3. doi: 10.1016/S0140-6736(25)00582. PubMedAbstract available
GIMENEZ-ARNAU AM, Pinter A, Sondermann W, Reguiai Z, et al Efficacy and safety of topical delgocitinib cream versus oral alitretinoin
capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week,
randomised, head-to-head, phase 3 trial.
Lancet. 2025;405:1676-1688. PubMedAbstract available
February 2025
GUTTMAN-YASSKY E, Renert-Yuval Y, Brunner PM Atopic dermatitis.
Lancet. 2025;405:583-596. PubMedAbstract available
DUNN JA, Donnelly P, Elbeltagi N, Marshall A, et al Annual versus less frequent mammographic surveillance in people with breast
cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised,
phase 3, non-inferiority trial.
Lancet. 2025;405:396-407. PubMedAbstract available
SABAT R, Alavi A, Wolk K, Wortsman X, et al Hidradenitis suppurativa.
Lancet. 2025;405:420-438. PubMedAbstract available
January 2025
FIORENTINO D, Mangold AR, Werth VP, Christopher-Stine L, et al Efficacy, safety, and target engagement of dazukibart, an IFNbeta specific
monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind,
randomised, placebo-controlled, phase 2 trial.
Lancet. 2025;405:137-146. PubMedAbstract available
December 2024
WEIDINGER S, Novak N Hand eczema.
Lancet. 2024;404:2476-2486. PubMedAbstract available
November 2024
CHONG DHY, Pasternak S, Taylor T, Armstrong S, et al Skin biopsy findings of dyskeratotic keratinocytes and vacuolar interface change
in a patient with Still's disease.
Lancet. 2024;404:e6. PubMed
SOMA T, Oie Y, Takayanagi H, Matsubara S, et al Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery:
a single-arm, open-label, first-in-human interventional study in Japan.
Lancet. 2024 Nov 7:S0140-6736(24)01764-1. doi: 10.1016/S0140-6736(24)01764. PubMedAbstract available
October 2024
JAIRATH V, Acosta Felquer ML, Jaihyun Cho R IL-23 inhibition for chronic inflammatory disease.
Lancet. 2024;404:1679-1692. PubMedAbstract available
Reductions in recurrence in women with early breast cancer entering clinical
trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials.
Lancet. 2024;404:1407-1418. PubMedAbstract available
TARANTINO P, Tolaney SM Progress in breast cancer management.
Lancet. 2024;404:1376-1378. PubMed
September 2024
NARAGHI K, Marzo-Ortega H Progressive cervical osteophytosis and dysphagia associated with isotretinoin
treatment for rosacea.
Lancet. 2024;404:e4. PubMed
August 2024
LEBWOHL MG, Thoma C, Haeufel T Spesolimab use in generalised pustular psoriasis flares - Authors' reply.
Lancet. 2024;404:847-848. PubMed
OSBORNE S, Thacker S, Kam O, Wescott R, et al Spesolimab use in generalised pustular psoriasis flares.
Lancet. 2024;404:846-847. PubMed
MANN GB, Rose AK, Zdenkowski N Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial -
Authors' reply.
Lancet. 2024;404:526. PubMed
KUNKLER I, Cameron D, Dixon M, Williams L, et al Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
Lancet. 2024;404:525. PubMed
SWANICK CW, Kelly P, Dvorak T, Mamounas EP, et al Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
Lancet. 2024;404:525-526. PubMed
MO DC, Huang JF, Luo PH, Wang HL, et al Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
Lancet. 2024;404:524-525. PubMed
RENERT-YUVAL Y, Guttman-Yassky E Hands-on: a novel JAK inhibitor for the treatment of chronic hand eczema.
Lancet. 2024;404:409-411. PubMed
July 2024
RUGO HS, Bardia A, Tolaney S Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial -
Authors' reply.
Lancet. 2024;404:339-340. PubMed
HARADA K, Ozaki A, Tanimoto T Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
Lancet. 2024;404:339. PubMed
MESSORI A Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
Lancet. 2024;404:338-339. PubMed
GU Y Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
Lancet. 2024;404:338. PubMed
ERGUN Y Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
Lancet. 2024;404:337-338. PubMed
ZUBERBIER T, Ensina LF, Gimenez-Arnau A, Grattan C, et al Chronic urticaria: unmet needs, emerging drugs, and new perspectives on
personalised treatment.
Lancet. 2024;404:393-404. PubMedAbstract available
BRUNNER PM A novel treatment approach for atopic dermatitis.
Lancet. 2024 Jul 25:S0140-6736(24)01488-0. doi: 10.1016/S0140-6736(24)01488. PubMed
SILVERBERG JI, Wollenberg A, Reich A, Thaci D, et al Nemolizumab with concomitant topical therapy in adolescents and adults with
moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two
replicate, double-blind, randomised controlled phase 3 trials.
Lancet. 2024 Jul 24:S0140-6736(24)01203-0. doi: 10.1016/S0140-6736(24)01203. PubMedAbstract available
BISSONNETTE R, Warren RB, Pinter A, Agner T, et al Efficacy and safety of delgocitinib cream in adults with moderate to severe
chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised,
controlled, double-blind, phase 3 trials.
Lancet. 2024 Jul 18:S0140-6736(24)01027-4. doi: 10.1016/S0140-6736(24)01027. PubMedAbstract available
June 2024
DELALOGE S, Khan SA, Wesseling J, Whelan T, et al Ductal carcinoma in situ of the breast: finding the balance between overtreatment
and undertreatment.
Lancet. 2024;403:2734-2746. PubMedAbstract available
MOLINELLI E, Simonetti O Bimekizumab: dual inhibition as a promising tool in the management of
hidradenitis suppurativa.
Lancet. 2024;403:2457-2459. PubMed
KIMBALL AB, Jemec GBE, Sayed CJ, Kirby JS, et al Efficacy and safety of bimekizumab in patients with moderate-to-severe
hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised,
double-blind, placebo-controlled, multicentre phase 3 trials.
Lancet. 2024 May 22:S0140-6736(24)00101-6. doi: 10.1016/S0140-6736(24)00101. PubMedAbstract available
PRASAD A Miriam Mutebi: transforming breast cancer care in Africa.
Lancet. 2024;403:1975. PubMed
COLES CE, Haviland JS, Kirby AM, Griffin C, et al Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial - Authors'
reply.
Lancet. 2024;403:1752. PubMed
GREGUCCI F, Ciabattoni A Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
Lancet. 2024;403:1751-1752. PubMed
MULLIEZ T, De Ridder M Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
Lancet. 2024;403:1751. PubMed
GUINOT JL, Gutierrez C, Hannoun-Levi JM Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
Lancet. 2024;403:1750-1751. PubMed
MIZUMOTO M, Oshiro Y, Sakurai H Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
Lancet. 2024;403:1749-1750. PubMed
ZHAO D, Li Y, Qu Y, He C, et al Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
Lancet. 2024;403:1749. PubMed
April 2024
DE SOUZA IC, Langer FW Post-radiation angiosarcoma of the breast in a patient with a history of invasive
ductal carcinoma.
Lancet. 2024;403:1681-1682. PubMed
MOODLEY J, Unger-Saldana K The role of racial and ethnic discrimination in breast cancer disparities.
Lancet. 2024 Apr 12:S0140-6736(24)00699-8. doi: 10.1016/S0140-6736(24)00699. PubMed
COLES CE, Earl H, Anderson BO, Barrios CH, et al The Lancet Breast Cancer Commission.
Lancet. 2024 Apr 12:S0140-6736(24)00747-5. doi: 10.1016/S0140-6736(24)00747. PubMed
SAMARASEKERA U Charlotte Coles: collaborating to tackle breast cancer inequities.
Lancet. 2024 Apr 12:S0140-6736(24)00752-9. doi: 10.1016/S0140-6736(24)00752. PubMed
EARL HM Safe de-escalation of chemotherapy in HER2-positive early breast cancer.
Lancet. 2024 Apr 3:S0140-6736(24)00535-X. doi: 10.1016/S0140-6736(24)00535. PubMed
PEREZ-GARCIA JM, Cortes J, Ruiz-Borrego M, Colleoni M, et al 3-year invasive disease-free survival with chemotherapy de-escalation using an
(18)F-FDG-PET-based, pathological complete response-adapted strategy in
HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2
trial.
Lancet. 2024 Apr 3:S0140-6736(24)00054-0. doi: 10.1016/S0140-6736(24)00054. PubMedAbstract available
March 2024
BRAYBROOKE J, Bradley R, Gray R, Hills R, et al Benefits and risks of anthracyclines in early-stage breast cancer - Authors'
reply.
Lancet. 2024;403:1240. PubMed
KUDE DE ALMEIDA F, Soares Falcetta F, Dornelles Rosa D Benefits and risks of anthracyclines in early-stage breast cancer.
Lancet. 2024;403:1239-1240. PubMed
EMMI G, Bettiol A, Hatemi G, Prisco D, et al Behcet's syndrome.
Lancet. 2024;403:1093-1108. PubMedAbstract available
HICKEY M, Basu P, Sassarini J, Stegmann ME, et al Managing menopause after cancer.
Lancet. 2024;403:984-996. PubMedAbstract available
February 2024
STONE GW, Christiansen EH, Ali ZA, Andreasen LN, et al Intravascular imaging-guided coronary drug-eluting stent implantation: an updated
network meta-analysis.
Lancet. 2024 Feb 21:S0140-6736(23)02454-6. doi: 10.1016/S0140-6736(23)02454. PubMedAbstract available